Individually, IGFBP-2, PKM2, and DKK3 exhibit limited diagnostic accuracy, but a combined panel has demonstrated improved performance, with 57% sensitivity for early-stage CRC, 76% for advanced stages, and 95% specificity, underscoring its potential as a non-invasive blood-based diagnostic tool [134]. The gene discussed is PKM; the disease is colorectal carcinoma.